774 results on '"Stölzel, Friedrich"'
Search Results
2. Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data
3. Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT
4. Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT
5. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
6. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
7. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
8. Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy
9. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
10. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
11. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison
12. Allogeneic Hematopoietic Stem Cell Transplantation From a CD36+ Donor in an Immunized Patient With Type I Hereditary CD36 Deficiency
13. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
14. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia
15. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany
16. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
17. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
18. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
19. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
20. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
21. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
22. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy
23. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
24. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia
25. Klonale Hämatopoese – Bedeutung für die Zelltherapie
26. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT
27. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
28. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT
29. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis
30. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation
31. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
32. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
33. Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study
34. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
35. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
36. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
37. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
38. Special Clinical Scenarios: Extramedullary Disease
39. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany
40. Clonal hematopoiesis and its emerging effects on cellular therapies
41. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation
42. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia
43. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
44. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
45. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma
46. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia - an EBMT registry analysis of 1540 patients
47. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
48. Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation
49. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
50. Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.